Literature DB >> 16933323

Protein-free fed-batch culture of non-GS NS0 cell lines for production of recombinant antibodies.

John E Burky1, Mark C Wesson, Amy Young, Sharyn Farnsworth, Ben Dionne, Ying Zhu, Taymar E Hartman, Limin Qu, Weichang Zhou, Paul W Sauer.   

Abstract

Presented is a novel antibody production platform based on the fed-batch culture of recombinant, NS0-derived cell lines. A standardized fed-batch cell culture process was developed for five non-GS NS0 cell lines using enriched and optimized protein-free, cholesterol-free, and chemically defined basal and feed media. The process performed reproducibly and scaled faithfully from the 2-L to the 100-L bioreactor scale achieving a volumetric productivity of > 120 mg/L per day. Fed-batch cultures for all five cell lines exhibited significant lactate consumption when the cells entered the stationary or death phase. Peak and final lactate concentrations were low relative to a previously developed fed-batch process (FBP). Such low lactate production and high lactate consumption rates were unanticipated considering the fed-batch culture basal medium has an unconventionally high initial glucose concentration of 15 g/L, and an overall glucose consumption in excess of 17 g/L. The potential of this process platform was further demonstrated through additional media optimization, which has resulted in a final antibody concentration of 2.64 +/- 0.19 g/L and volumetric productivity of > 200 mg/L per day in a 13-day FBP for one of the five production cell lines. Use of this standardized protein-free, cholesterol-free NS0 FBP platform enables consistency in development time and cost effectiveness for manufacturing of therapeutic antibodies. (c) 2006 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 16933323     DOI: 10.1002/bit.21060

Source DB:  PubMed          Journal:  Biotechnol Bioeng        ISSN: 0006-3592            Impact factor:   4.530


  7 in total

Review 1.  Cell culture processes for monoclonal antibody production.

Authors:  Feng Li; Natarajan Vijayasankaran; Amy Yijuan Shen; Robert Kiss; Ashraf Amanullah
Journal:  MAbs       Date:  2010-09-01       Impact factor: 5.857

2.  Optimization of bioprocess conditions improves production of a CHO cell-derived, bioengineered heparin.

Authors:  Jong Youn Baik; Hussain Dahodwala; Eziafa Oduah; Lee Talman; Trent R Gemmill; Leyla Gasimli; Payel Datta; Bo Yang; Guoyun Li; Fuming Zhang; Lingyun Li; Robert J Linhardt; Andrew M Campbell; Stephen F Gorfien; Susan T Sharfstein
Journal:  Biotechnol J       Date:  2015-06-24       Impact factor: 4.677

3.  Combination of yeast hydrolysates to improve CHO cell growth and IgG production.

Authors:  Mathilde Mosser; Isabelle Chevalot; Eric Olmos; Fabrice Blanchard; Romain Kapel; Eric Oriol; Ivan Marc; Annie Marc
Journal:  Cytotechnology       Date:  2012-12-14       Impact factor: 2.058

4.  Expression of recombinant antibodies.

Authors:  André Frenzel; Michael Hust; Thomas Schirrmann
Journal:  Front Immunol       Date:  2013-07-29       Impact factor: 7.561

5.  Recombinant production of the antibody fragment D1.3 scFv with different Bacillus strains.

Authors:  Antonia Lakowitz; Rainer Krull; Rebekka Biedendieck
Journal:  Microb Cell Fact       Date:  2017-01-23       Impact factor: 5.328

Review 6.  Innovations in the Insect Cell Expression System for Industrial Recombinant Vaccine Antigen Production.

Authors:  Manon M J Cox
Journal:  Vaccines (Basel)       Date:  2021-12-20

7.  A Simple Method to Reduce both Lactic Acid and Ammonium Production in Industrial Animal Cell Culture.

Authors:  Nathaniel W Freund; Matthew S Croughan
Journal:  Int J Mol Sci       Date:  2018-01-28       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.